Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.1% – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 5.1% during mid-day trading on Tuesday . The company traded as low as $6.15 and last traded at $6.25. 11,376,722 shares changed hands during trading, a decline of 56% from the average session volume of 25,701,658 shares. The stock had previously closed at $6.59.

Analyst Ratings Changes

Several research analysts have weighed in on RXRX shares. Leerink Partners cut their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday. KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Trading Down 1.8 %

The business’s 50-day simple moving average is $7.71 and its two-hundred day simple moving average is $7.09. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.53 billion, a PE ratio of -4.23 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.42) EPS. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $27,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.